## Yazdan Yazdanpanah

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2128985/publications.pdf

Version: 2024-02-01

48 papers

4,607 citations

20 h-index 197818 49 g-index

56 all docs 56
docs citations

56 times ranked 10901 citing authors

#	Article	IF	CITATIONS
1	Multicenter study on recent portal venous system thrombosis associated with cytomegalovirus disease. Journal of Hepatology, 2022, 76, 115-122.	3.7	6
2	Alpha (B.1.1.7) and Delta (B.1.617.2 – AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage. Journal of Infection, 2022, 84, 418-467.	3.3	4
3	Screening and vaccination against COVID-19 to minimise school closure: a modelling study. Lancet Infectious Diseases, The, 2022, 22, 977-989.	9.1	37
4	Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVIDâ€19 patients. Journal of Medical Virology, 2021, 93, 2149-2159.	5.0	35
5	Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives. Clinical Microbiology and Infection, 2021, 27, 789.e1-789.e5.	6.0	52
6	Nebulised interferon beta-1a for patients with COVID-19. Lancet Respiratory Medicine, the, 2021, 9, 122-123.	10.7	32
7	Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial—authors' response. Journal of Antimicrobial Chemotherapy, 2021, 76, 277-279.	3.0	2
8	Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	181
9	Chronic use of reninâ€angiotensinâ€aldosterone system blockers and mortality in COVIDâ€19: A multicenter prospective cohort and literature review. Fundamental and Clinical Pharmacology, 2021, 35, 1141-1158.	1.9	4
10	COVID-19 vaccines: A race against time. Anaesthesia, Critical Care & Eamp; Pain Medicine, 2021, 40, 100848.	1.4	11
11	High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort. Journal of Infection, 2021, 82, 186-230.	3.3	7
12	Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial. Lancet HIV,the, 2021, 8, e324-e333.	4.7	24
13	Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (March–May 2020). Clinical Microbiology and Infection, 2021, 27, 1520.e1-1520.e5.	6.0	12
14	CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death. IScience, 2021, 24, 102711.	4.1	79
15	Sociodemographic characteristics and transmission risk factors in patients hospitalized for COVID-19 before and during the lockdown in France. BMC Infectious Diseases, 2021, 21, 812.	2.9	4
16	Chronicles of a pandemic: How France coordinated the scientific research response to COVID-19. Infectious Diseases Now, 2021, 51, 641-646.	1.6	1
17	Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries. Trials, 2021, 22, 86.	1.6	9
18	Temporal Trends in Suicide Attempts Among Children in the Decade Before and During the COVID-19 Pandemic in Paris, France. JAMA Network Open, 2021, 4, e2128611.	5.9	42

#	Article	IF	CITATIONS
19	Health status and healthcare trajectory of vulnerable asylum seekers hosted in a French Reception Center. Travel Medicine and Infectious Disease, 2021, , 102180.	3.0	3
20	COVID-19: France grapples with the pragmatics of isolation. Lancet Public Health, The, 2020, 5, e573-e574.	10.0	13
21	SARS-COV2 infection in 30 HIV-infected patients followed-up in a French University Hospital. International Journal of Infectious Diseases, 2020, 101, 49-51.	3.3	15
22	France's COVID-19 response: balancing conflicting public health traditions. Lancet, The, 2020, 396, 219-221.	13.7	20
23	Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia. Cell Reports Medicine, 2020, 1, 100059.	6.5	188
24	A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations. Science Translational Medicine, 2020, 12, .	12.4	228
25	Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIVâ€infected patients. British Journal of Clinical Pharmacology, 2020, 86, 2404-2413.	2.4	6
26	Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 2376-2380.	3.0	25
27	Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infectious Diseases, The, 2020, 20, 697-706.	9.1	953
28	Case report study of the first five COVID-19 patients treated with remdesivir in France. International Journal of Infectious Diseases, 2020, 98, 290-293.	3.3	30
29	Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study. Lancet, The, 2020, 395, 871-877.	13.7	931
30	Type 1 interferons as a potential treatment against COVID-19. Antiviral Research, 2020, 178, 104791.	4.1	425
31	HIV Infection in North African Patients. AIDS Research and Human Retroviruses, 2019, 35, 628-633.	1.1	1
32	Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV,the, 2019, 6, e355-e363.	4.7	107
33	Concentration–response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients. Journal of Antimicrobial Chemotherapy, 2019, 74, 1992-2002.	3.0	8
34	HepCare Europe: a new user-friendly hepatitis C care service model. What have we learned? What are the remaining challenges?. Journal of Antimicrobial Chemotherapy, 2019, 74, v2-v4.	3.0	0
35	Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. European Journal of Clinical Pharmacology, 2018, 74, 473-481.	1.9	6
36	Prevention of Ebola virus disease through vaccination: where we are in 2018. Lancet, The, 2018, 392, 787-790.	13.7	103

#	Article	IF	CITATIONS
37	Vaccination and blood sampling acceptability during Ramadan fasting month: A cross-sectional study in Conakry, Guinea. Vaccine, 2017, 35, 2569-2574.	3.8	10
38	Evidence of Sexual Transmission of Zika Virus. New England Journal of Medicine, 2016, 374, 2195-2198.	27.0	632
39	Long-Lasting Persistence of Zika Virus in Semen. Clinical Infectious Diseases, 2016, 63, ciw509.	5.8	57
40	Reply to: "Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal diseaseâ€. Journal of Hepatology, 2016, 65, 1065-1066.	3.7	1
41	Zika virus infection: report of the first imported cases in a Paris travel centre: Table 1. Journal of Travel Medicine, 2016, 24, taw066.	3.0	14
42	Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. Journal of Hepatology, 2016, 65, 40-47.	3.7	161
43	A Case of Aggregatibacter aphrophilus Multiple Abscess. Open Forum Infectious Diseases, 2015, 2, ofv031.	0.9	6
44	Sternal Wound Infection after Cardiac Surgery: Management and Outcome. PLoS ONE, 2015, 10, e0139122.	2.5	21
45	Predictors of return rate for an HIV-positive result in a French Voluntary Counseling and Testing centre. International Journal of STD and AIDS, 2015, 26, 33-36.	1.1	7
46	Drug assessment in the Ebola virus disease epidemic in west Africa. Lancet Infectious Diseases, The, 2015, 15, 1258.	9.1	8
47	HIV-serodiscordant couples desiring a child: †treatment as prevention,†preexposure prophylaxis, or medically assisted procreation?. American Journal of Obstetrics and Gynecology, 2015, 213, 341.e1-341.e12.	1.3	13
48	Trends in Condom Use and Risk Behaviours after Sexual Exposure to HIV: A Seven-Year Observational Study. PLoS ONE, 2014, 9, e104350.	2.5	13